{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89.8","upperLimit":"98.2","value":"95.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"}],"units":"Participants"}],"title":"CLL/SLL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88.5","upperLimit":"99.1","value":"95.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"}],"units":"Participants"}],"title":"WM"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70.1","upperLimit":"91.3","value":"82.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"title":"MCL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.1","upperLimit":"96.8","value":"85.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"MZL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.4","upperLimit":"54.9","value":"36.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"FL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.7","upperLimit":"57.8","value":"42.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"DLBCL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.6","upperLimit":"86.1","value":"61.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"RT"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.7","upperLimit":"84.8","value":"58.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"HCL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"378"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants with partial or complete response (CR), as assessed by the investigator. For CLL/SLL, ORR includes partial response (PR) with lymphocytosis (PR-L) or better (includes PR-L, PR, nodular PR or nPR and CR with incomplete marrow recovery or CRi) and for MW, ORR includes minor response or better. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).","dispersionType":"95% Confidence Interval","groups":[{"description":"The dose regimens from Part 1 (40 mg, 80 mg, 160 mg QD, 160 mg BID and 320 mg QD) and Part 2 (160 mg BID and 320 mg QD) were evaluated in different disease types. Efficacy evaluations are reported by disease type for Parts 1 and 2 combined, as pre-specified in the statistical analysis plan.","id":"OG000","title":"Part 1 and Part 2: Overall"}],"paramType":"NUMBER","populationDescription":"Efficacy Evaluable Set consists of all participants who received at least one dose of zanubrutinib; for WM, participants also must have a baseline IgM (or M-protein) ≥ 5 g/L and no prior exposure to a BTK inhibitor.","reportingStatus":"POSTED","timeFrame":"Up to 6 years and 7 months","title":"Part 1 and Part 2: Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}